PMID- 24096053
OWN - NLM
STAT- MEDLINE
DCOM- 20140801
LR  - 20151119
IS  - 1878-4216 (Electronic)
IS  - 0278-5846 (Linking)
VI  - 48
DP  - 2014 Jan 3
TI  - BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated 
      with desvenlafaxine.
PG  - 86-91
LID - S0278-5846(13)00211-X [pii]
LID - 10.1016/j.pnpbp.2013.09.016 [doi]
AB  - BACKGROUND: Relationships between brain-derived neurotrophic factor (BDNF), 
      interleukin (IL)-6, and salivary cortisol and both depression severity and 
      treatment response were assessed in patients enrolled in a double-blind, 
      placebo-controlled trial of desvenlafaxine 50mg/d for MDD. METHODS: Outpatients 
      with MDD were randomly assigned to 12weeks of double-blind treatment with 
      desvenlafaxine 50mg/d or placebo (2:1). Baseline severity was assessed using the 
      17-item Hamilton Rating Scale for Depression (HAM-D17); treatment response at 
      week 12 was based on HAM-D17 total score and response and remission status. 
      Saliva (cortisol) and blood (BDNF, IL-6) samples for biomarker assay were 
      collected at baseline and week 12. Spearman correlations were calculated between 
      the biomarkers at baseline, and between biomarkers and HAM-D17 total score at 
      baseline. Logistic regression analyses were used to assess whether baseline 
      biomarker levels predicted treatment response at week 12, with and without 
      adjustment for baseline HAM-D17 score, treatment, and geographic region. 
      Similarly, an analysis of covariance was used to assess whether baseline disease 
      severity predicted biomarker change at week 12. RESULTS: A total of 427 patients 
      who received >/=1 dose of study drug and had baseline and >/=1 on-therapy primary 
      efficacy evaluations were included in the analysis. At baseline, there was a 
      statistically significant although weak correlation between levels of IL-6 and 
      BDNF (Spearman correlation coefficient [rs]=0.120; P=0.014), but no significant 
      correlation between baseline biomarker levels and baseline HAM-D17 total score 
      (absolute value of all rs, </=0.061). Desvenlafaxine 50mg/d treatment significantly 
      reduced HAM-D17 total score from baseline at week 12 compared with placebo 
      (P=0.006), but the three potential biomarkers did not predict treatment effects. 
      No significant correlations were observed between the change from baseline in any 
      biomarker level and change in HAM-D17 total score at week 12, either overall, or 
      in desvenlafaxine or placebo groups (absolute value of all rs, 0.003-0.196). 
      Baseline levels of BDNF, IL-6, and salivary cortisol did not significantly 
      predict response to treatment at week 12. Although median increase in BDNF was 
      not significantly different between desvenlafaxine (13.7%) and placebo (5.7%) 
      groups, the increase was significantly greater (33.4% vs 4.3%; P=0.003) in 
      patients with more severe depression at baseline (HAM-D17>22) vs those with less 
      severe depression (HAM-D17</=22). No similar findings were observed for IL-6 or 
      salivary cortisol. DISCUSSION: Weak or no relationships were observed at baseline 
      between the potential biomarkers or between biomarkers and disease severity. 
      While baseline biomarker level did not predict treatment response, improvement in 
      BDNF was significantly greater among patients who were more severely depressed at 
      baseline.
CI  - (c) 2013.
FAU - Ninan, Philip T
AU  - Ninan PT
AD  - East Carolina University, Greenville, NC, United States; Formerly of Pfizer Inc., 
      Collegeville, PA, United States. Electronic address: philiptninan@gmail.com.
FAU - Shelton, Richard C
AU  - Shelton RC
FAU - Bao, Weihang
AU  - Bao W
FAU - Guico-Pabia, Christine J
AU  - Guico-Pabia CJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20131002
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cyclohexanols)
RN  - 0 (Interleukin-6)
RN  - WI4X0X7BPJ (Hydrocortisone)
RN  - ZB22ENF0XR (Desvenlafaxine Succinate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cyclohexanols/*therapeutic use
MH  - Depression/*drug therapy/metabolism
MH  - Desvenlafaxine Succinate
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydrocortisone/*metabolism
MH  - Interleukin-6/*blood
MH  - Male
MH  - Middle Aged
MH  - Outpatients
MH  - Psychiatric Status Rating Scales
MH  - Saliva/metabolism
MH  - Severity of Illness Index
MH  - Statistics as Topic
MH  - Young Adult
OTO - NOTNLM
OT  - 17-item Hamilton Rating Scale for Depression
OT  - BDNF
OT  - Brain-derived neurotrophic factor
OT  - Depression
OT  - Desvenlafaxine
OT  - HAM-D(17)
OT  - IL
OT  - Interleukin 6
OT  - MADRS
OT  - MDD
OT  - Montgomery-Asberg Depression Rating Scale
OT  - NGF
OT  - NT
OT  - SDS
OT  - Salivary cortisol
OT  - Sheehan Disability Scale
OT  - Spearman correlation coefficient
OT  - brain-derived neurotrophic factor
OT  - interleukin
OT  - major depressive disorder
OT  - nerve growth factor
OT  - neurotrophin
OT  - rs
EDAT- 2013/10/08 06:00
MHDA- 2014/08/02 06:00
CRDT- 2013/10/08 06:00
PHST- 2013/03/06 00:00 [received]
PHST- 2013/09/16 00:00 [revised]
PHST- 2013/09/25 00:00 [accepted]
PHST- 2013/10/08 06:00 [entrez]
PHST- 2013/10/08 06:00 [pubmed]
PHST- 2014/08/02 06:00 [medline]
AID - S0278-5846(13)00211-X [pii]
AID - 10.1016/j.pnpbp.2013.09.016 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:86-91. doi: 
      10.1016/j.pnpbp.2013.09.016. Epub 2013 Oct 2.